Originally posted by Daisycat
View Post
Announcement
Collapse
No announcement yet.
New neuro
Collapse
X
-
He is your friend, your partner, your defender, your dog. You are his life, his love, his leader. He will be yours, faithful and true to the last beat of his heart. You owe it to him to be worthy of such devotion.
Anonymous
-
Originally posted by Daisycat View PostMamabug
I think sea salt is what I have been using when I do use salt. I have been trying so hard to avoid it I am not really sure what type I have (if any). I know I have been slacking the past few days on my diet and I can defiantly tell the difference. I have less energy and don’t want to really do anything.
In contrast, most sea salt is naturally harvested and dried and minimally processed. They contain a wealth of trace minerals and electrolytes that are healthy for us, not detrimental.
Again, this is natural sea salt that you buy at a health food store. Not Morton's from the grocery store.~ Faith
MSWorld Volunteer -- Moderator since JUN2012
(now a Mimibug)
Symptoms began in JAN02
- Dx with RRMS in OCT03, following 21 months of limbo, ruling out lots of other dx, and some "probable stroke" and "probable CNS" dx for awhile.
- In 2008, I was back in limbo briefly, then re-dx w/ MS: JUL08.
- Betaseron NOV03-AUG08; Copaxone20 SEPT08-APR15; Copaxone40 APR15-present
- Began receiving SSDI / LTD NOV08. Not employed. I volunteer in my church and community.
Comment
-
Anyone with any info/experience on lipoic acid? I was looking an article, haven't gotten the actual article yet and I didn't see in the abstract the number of participants which is important to me when considering validity.
Quoted from https://www.ncbi.nlm.nih.gov/pmc/art...C5331099/#CR35
"Moreover, Khalili et al. found a strong correlation between oral intake of lipoic acid (1.2 mg/day) and decrease in the levels of pro-inflammatory cytokines, including INF-γ, ICAM-1, and anti-inflammatory cytokines, including TGF-β and IL-4, compared with placebo group"
Khalili M, Azimi A, Izadi V, et al. Does lipoic acid consumption affect the cytokine profile in multiple sclerosis patients: a double-blind, placebo-controlled, randomized clinical trial. Neuroimmunomodulation. 2014;21(6):291–296.He is your friend, your partner, your defender, your dog. You are his life, his love, his leader. He will be yours, faithful and true to the last beat of his heart. You owe it to him to be worthy of such devotion.
Anonymous
Comment
-
Hello, here is study suggesting benefit of Alpha Lipoic Acid in SPMS...
Alpha Lipoic Acid for neuroprotection in secondary progressive multiple sclerosis: results of a randomized placebo-controlled pilot trial
ECTRIMS Online Library. Spain R. Sep 16, 2016; 147064
Abstract Category: Therapy - disease modifying - Treatment of progressive MS
Objective: To determine if Lipoic acid (LA) is neuroprotective, reduces disability and improves quality of life, and is safe in a secondary progressive multiple sclerosis (SPMS) population.
Background: LA is an inexpensive and readily-available oral antioxidant. In the animal model of MS, LA decreases inflammation and reduces optic nerve and spinal cord atrophy. LA reaches therapeutic blood levels and is tolerated at high doses in people with MS...
Methods: A 96 week, double-blind, randomized controlled trial of 1200mg daily LA versus placebo. Primary outcome was reduction in MRI whole brain atrophy. Secondary outcomes included atrophy of brain substructures and spinal cord, retinal and macular atrophy, changes in neurological exam, walking, cognition, fatigue, and quality of life...
Results: Of the 54 randomized participants, 51 (27 LA and 24 placebo) took at least one dose of study drug and were included in analysis.... Annualized rate of whole brain atrophy was significantly lower at 96 weeks in the LA group compared to placebo (slope= -0.22 vs. -0.65, p=0.004). On treatment, two-year volume loss was -0.4 % (0.7) for LA and (-1.3 % (1.1) for placebo (p=0.006). Walking speed improved in the LA group (p=0.057).
Conclusions: This highly promising pilot trial of LA demonstrated a significant reduction in whole brain atrophy and suggested a clinical benefit in SPMS while maintaining safety, tolerability, and high compliance over 96 weeks. A larger trial is necessary to confirm the neuroprotective effects, explore clinical benefits, and ensure the safety of LA in progressive MS populations.
Comment
-
Originally posted by Myoak View PostHello, here is study suggesting benefit of Alpha Lipoic Acid in SPMS...
Alpha Lipoic Acid for neuroprotection in secondary progressive multiple sclerosis: results of a randomized placebo-controlled pilot trial
ECTRIMS Online Library. Spain R. Sep 16, 2016; 147064
Abstract Category: Therapy - disease modifying - Treatment of progressive MS
Objective: To determine if Lipoic acid (LA) is neuroprotective, reduces disability and improves quality of life, and is safe in a secondary progressive multiple sclerosis (SPMS) population.
Background: LA is an inexpensive and readily-available oral antioxidant. In the animal model of MS, LA decreases inflammation and reduces optic nerve and spinal cord atrophy. LA reaches therapeutic blood levels and is tolerated at high doses in people with MS...
Methods: A 96 week, double-blind, randomized controlled trial of 1200mg daily LA versus placebo. Primary outcome was reduction in MRI whole brain atrophy. Secondary outcomes included atrophy of brain substructures and spinal cord, retinal and macular atrophy, changes in neurological exam, walking, cognition, fatigue, and quality of life...
Results: Of the 54 randomized participants, 51 (27 LA and 24 placebo) took at least one dose of study drug and were included in analysis.... Annualized rate of whole brain atrophy was significantly lower at 96 weeks in the LA group compared to placebo (slope= -0.22 vs. -0.65, p=0.004). On treatment, two-year volume loss was -0.4 % (0.7) for LA and (-1.3 % (1.1) for placebo (p=0.006). Walking speed improved in the LA group (p=0.057).
Conclusions: This highly promising pilot trial of LA demonstrated a significant reduction in whole brain atrophy and suggested a clinical benefit in SPMS while maintaining safety, tolerability, and high compliance over 96 weeks. A larger trial is necessary to confirm the neuroprotective effects, explore clinical benefits, and ensure the safety of LA in progressive MS populations.He is your friend, your partner, your defender, your dog. You are his life, his love, his leader. He will be yours, faithful and true to the last beat of his heart. You owe it to him to be worthy of such devotion.
Anonymous
Comment
-
Originally posted by Jules A View PostThanks! Tiny n but nice time frame and excellent results.
If pharma could patent Alpha Lipoic Acid large, multi-year studies with hundreds or thousands would already have taken place. Large studies of ALA will never occur because there is no financial reason justifying them.
You may want to check out Dr. Burt Berkson's book... The Alpha Lipoic Acid Breakthrough. He outlines several huge health benefits and was the CDC's principle investigator on ALA for decades. As a note... I have taken family members to Berkson's practice in New Mexico. He retired but his son has the practice now.
BTW, my mother (still at her home living on her own) will turn 99 in two months has taken ALA for years.
Comment
Comment